1. Home
  2. LEGN vs ITRI Comparison

LEGN vs ITRI Comparison

Compare LEGN & ITRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEGN
  • ITRI
  • Stock Information
  • Founded
  • LEGN 2014
  • ITRI 1977
  • Country
  • LEGN United States
  • ITRI United States
  • Employees
  • LEGN N/A
  • ITRI N/A
  • Industry
  • LEGN Biotechnology: Pharmaceutical Preparations
  • ITRI Electrical Products
  • Sector
  • LEGN Health Care
  • ITRI Industrials
  • Exchange
  • LEGN Nasdaq
  • ITRI Nasdaq
  • Market Cap
  • LEGN 5.4B
  • ITRI 5.6B
  • IPO Year
  • LEGN 2020
  • ITRI 1993
  • Fundamental
  • Price
  • LEGN $34.00
  • ITRI $128.08
  • Analyst Decision
  • LEGN Strong Buy
  • ITRI Strong Buy
  • Analyst Count
  • LEGN 12
  • ITRI 10
  • Target Price
  • LEGN $77.09
  • ITRI $126.80
  • AVG Volume (30 Days)
  • LEGN 2.0M
  • ITRI 521.4K
  • Earning Date
  • LEGN 08-08-2025
  • ITRI 07-31-2025
  • Dividend Yield
  • LEGN N/A
  • ITRI N/A
  • EPS Growth
  • LEGN N/A
  • ITRI 57.53
  • EPS
  • LEGN N/A
  • ITRI 5.48
  • Revenue
  • LEGN $728,303,000.00
  • ITRI $2,444,546,000.00
  • Revenue This Year
  • LEGN $65.49
  • ITRI $2.96
  • Revenue Next Year
  • LEGN $53.76
  • ITRI $5.89
  • P/E Ratio
  • LEGN N/A
  • ITRI $23.29
  • Revenue Growth
  • LEGN 112.46
  • ITRI 7.10
  • 52 Week Low
  • LEGN $27.34
  • ITRI $90.11
  • 52 Week High
  • LEGN $60.87
  • ITRI $129.83
  • Technical
  • Relative Strength Index (RSI)
  • LEGN 53.16
  • ITRI 76.28
  • Support Level
  • LEGN $33.84
  • ITRI $121.00
  • Resistance Level
  • LEGN $35.29
  • ITRI $125.40
  • Average True Range (ATR)
  • LEGN 1.96
  • ITRI 2.27
  • MACD
  • LEGN 0.24
  • ITRI 0.43
  • Stochastic Oscillator
  • LEGN 52.16
  • ITRI 92.38

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

About ITRI Itron Inc.

Itron Inc provides solutions that measure, manage, and analyze energy and water use. It operates under the Itron brand and manages and reports under three operating segments: Device Solutions, Networked Solutions, and Outcomes. The Device Solutions segment includes hardware products used for measurement, control, or sense that do not have communications capability embedded for use with broader Itron systems. The Networked Solutions segment includes a combination of communicating devices, network infrastructure, and associated application software designed and sold as a complete solution. The Outcome segment includes their value-added, enhanced software and services which manage, organize, analyze, and interpret data to improve decision-making and maximize operational profitability.

Share on Social Networks: